We pursue the two major development strategies, namely, to “strengthen research and development of our innovative drug candidates” and “continue to strengthen our first-to-market generic drug portfolio”. Apart from the 13 marketed main products, we own a diversified pipeline of Category 1.1 innovative drugs and potential first-to-market generic drug candidates in different stages of development. Our sales team helps promote our current core products and drugs with strong growth potential.Up to now, our sales and marketing team covers 30 provinces, municipalities and autonomous regions in China
Hansoh closely follows up the developments in global medical frontiers, joint hands with key medical institutions and large scientific and research institutes via diversified international and domestic collaborations such as academic conferences, clinical studies and talent training to improve China’s overall medical care level